[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 1, 2003

Effects of Estrogen Plus Progestin on Risk of Dementia—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;290(13):1706-1708. doi:10.1001/jama.290.13.1706-a

To the Editor: Dr Shumaker and colleagues1 from the Women's Health Initiative Memory Study (WHIMS) reported that combined equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) increased the risk for probable dementia in postmenopausal women aged 65 years or older. They also found that this regimen did not prevent mild cognitive impairment. These findings are consistent with our data that MPA antagonizes the neuroprotective and memory mechanisms of estrogen.24 These studies, conducted while the WHIMS trial was in progress, indicate that progestins have differing profiles of biochemical and genomic activation that lead to differential effects on beneficial estrogen-inducible mechanisms.5 Results of these analyses could be used to predict efficacy of hormone therapy formulations for prevention of Alzheimer disease (AD). The challenge remains to develop a therapeutic strategy for promoting the beneficial effects of estrogen in the brain while preventing untoward consequences of estrogen in other organ systems.

First Page Preview View Large
First page PDF preview
First page PDF preview
×